Cytora is a clinical‑stage biotech company developing a first‑in‑class, off‑the‑shelf cell therapy platform based on human oral mucosa stem cells (hOMSCs), a neural‑crest–derived allogeneic cell population. The platform has already shown strong safety and promising efficacy in two programs: hOMSC200 for hard‑to‑heal diabetic foot ulcers, and hOMSC300 for multiple system atrophy, with early signs of slowed disease progression